Zogenix (ZGNX) Plans Public Offering of Common Stock

Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Zogenix.

Zogenix intends to use the net proceeds from the proposed offering to support its activities related to the potential commercialization of FINTEPLA® for the treatment of Dravet syndrome, submission of regulatory applications in the United States and the European Union for FINTEPLA for the treatment of Lennox-Gastaut syndrome, funding of future clinical trials of FINTEPLA for other indications, continuing development and activities related to the potential commercialization of MT1621 for the treatment of thymidine kinase 2 deficiency, and for working capital and general corporate purposes.

SVB Leerink and Stifel are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

You May Also Be Interested In

• Cardinal Infrastructure Group proposes stock offering of 3.75M shares
• PebbleBrook Hotel Trust (PEB) PT Raised to $20.25 at Stifel after Mgmt Meetings
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy